These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32839771)

  • 1. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.
    Chen CZ; Shinn P; Itkin Z; Eastman RT; Bostwick R; Rasmussen L; Huang R; Shen M; Hu X; Wilson KM; Brooks B; Guo H; Zhao T; Klump-Thomas C; Simeonov A; Michael SG; Lo DC; Hall MD; Zheng W
    bioRxiv; 2020 Aug; ():. PubMed ID: 32839771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.
    Chen CZ; Shinn P; Itkin Z; Eastman RT; Bostwick R; Rasmussen L; Huang R; Shen M; Hu X; Wilson KM; Brooks BM; Guo H; Zhao T; Klump-Thomas C; Simeonov A; Michael SG; Lo DC; Hall MD; Zheng W
    Front Pharmacol; 2020; 11():592737. PubMed ID: 33708112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
    Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
    ACS Pharmacol Transl Sci; 2020 Oct; 3(5):1008-1016. PubMed ID: 33062953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay.
    Jang WD; Jeon S; Kim S; Lee SY
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34234012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.
    Rodon J; Muñoz-Basagoiti J; Perez-Zsolt D; Noguera-Julian M; Paredes R; Mateu L; Quiñones C; Perez C; Erkizia I; Blanco I; Valencia A; Guallar V; Carrillo J; Blanco J; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N
    Front Pharmacol; 2021; 12():646676. PubMed ID: 33841165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2.
    Xiao X; Wang C; Chang D; Wang Y; Dong X; Jiao T; Zhao Z; Ren L; Dela Cruz CS; Sharma L; Lei X; Wang J
    Front Immunol; 2020; 11():586572. PubMed ID: 33324406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing old drugs as antiviral agents for coronaviruses.
    Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
    Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.
    Kouznetsova J; Sun W; Martínez-Romero C; Tawa G; Shinn P; Chen CZ; Schimmer A; Sanderson P; McKew JC; Zheng W; García-Sastre A
    Emerg Microbes Infect; 2014 Dec; 3(12):e84. PubMed ID: 26038505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase.
    Bertolin AP; Weissmann F; Zeng J; Posse V; Milligan JC; Canal B; Ulferts R; Wu M; Drury LS; Howell M; Beale R; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2425-2443. PubMed ID: 34198323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
    Wang S; Sun Q; Xu Y; Pei J; Lai L
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach.
    Abdel-Halim H; Hajar M; Hasouneh L; Abdelmalek SMA
    Drug Des Devel Ther; 2022; 16():2995-3013. PubMed ID: 36110398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
    Pohl MO; Busnadiego I; Marrafino F; Wiedmer L; Hunziker A; Fernbach S; Glas I; Moroz-Omori EV; Hale BG; Caflisch A; Stertz S
    J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34319869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
    Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
    SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling repurposable drug combinations against COVID-19 by developing the heterogeneous deep herb-graph method.
    Yang F; Zhang S; Pan W; Yao R; Zhang W; Zhang Y; Wang G; Zhang Q; Cheng Y; Dong J; Ruan C; Cui L; Wu H; Xue F
    Brief Bioinform; 2022 Sep; 23(5):. PubMed ID: 35514205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
    Zhao Y; Du X; Duan Y; Pan X; Sun Y; You T; Han L; Jin Z; Shang W; Yu J; Guo H; Liu Q; Wu Y; Peng C; Wang J; Zhu C; Yang X; Yang K; Lei Y; Guddat LW; Xu W; Xiao G; Sun L; Zhang L; Rao Z; Yang H
    Protein Cell; 2021 Nov; 12(11):877-888. PubMed ID: 33864621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.